Company: APXIF
Filing Date: 2025-06-13
Form Type: F-4/A
Source: 0001213900-25-054324
Chunk: 414

Company: APx Acquisition Corp. I
Filing Date: 2025-06-13
Form: F-4/A
Chunk 414
---
7.8 | )% |
| Total other comprehensive income/(loss) |     |                 (200,548 | ) |     |    (11,780 | ) |     |   (188,768 | ) |     |    1602.4 | %  |
| Total comprehensive loss for the year   |     |               (1,522,854 | ) |     | (1,446,464 | ) |     |    (76,390 | ) |     |       5.3 | %  |
| Basic and diluted loss per share        |     |                    (0.04 | ) |     |      (0.05 | ) |     |       0.01 |   |     |        20 | %  |

____________ Notes: n.m. — not meaningful. Revenues Revenues increased by $131,390, or 18.7%, from $703,392 for the six months ended December 31, 2023, to $834,782 for the six months ended December 31, 2024. Revenues from the Heritas Diagnostics segment increased by $24,270, or 3.6%, from $672,336 for the six months ended December 31, 2023, to $696,606 for the six months ended December 31, 2024. The increase was entirely attributable to a price effect, as the number of samples processed remained substantially consistent between periods, indicating a neutral volume effect.

212 Revenues from the Rewell segment increased by $107,120, or 344.9%, from $31,056 for the six months ended December 31, 2023, to $138,176 for the six months ended December 31, 2024. This growth is explained as follows: • volume effect: 79% of the increase is due to a 61% growth in the number of kits sold, reflecting expanded commercialization efforts and improved sales strategies; and • price effect: 21% of the increase is due to a 20% rise in the average price per kit, which is quoted in U.S. dollars, driven by adjustments in pricing strategies and increased direct -to -consumersales. Overall, approximately 83% and 17% of total revenues were derived from the Heritas Diagnostics segment and the Rewell segment, respectively, in the six months ended December 31, 2024, compared to 95.6% and 4.